Eli Lilly and Company (LLY) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q1 2026 earnings conference call. At this time, all participants are in a listen-only mode. Later, we will be conducting a question and answer session and instructions will be given at that time. Should you require assistance during the call, please press star then zero and an operator will assist you offline. I would now like to turn the conference over to your host, Mike Zappar, Senior Vice President of Investor Relations. Please go ahead. Good morning. Thank you for joining us for Eli Lilly and Company's Q1 2026 earnings call. I'm Mike Sabar, Senior Vice President of Investor Relations. Joining me on today's call are Dave Ricks, Lilly's Chair and CEO. Lucas Montarse, Chief Financial Officer. Dr. Dan Skowromski, Chief Scientific and Product Officer. Adrian Brown, President of Lilly Immunology. Dr. Carol Ho, President of Lilly Neuroscience. Ilya Yufa, President of Lilly USA and Global Customer Capabilities. Jake Van Narden, President of Lillian College, Head of Business Development. Patrick Gonson, President of Lilly International. And Ken Custer, President of Lilly Cardiometabolic Health. We're also joined by the investor relations team, Kim Griffey, Susan Hedgeland, Mark Keeman, and Wes Paul. During this call, we anticipate making projections and forward-looking statements based on our current expectations. Our actual results could differ materially due to various factors, including those listed on slide four. Additional information concerning factors that could cause actual results to differ materially is contained in our latest Form 10-K and subsequent filings with the SEC. The information we provide about our products and pipeline is for the benefit of the investment community and intended...